Entero Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2017 to Q1 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Entero Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2017 to Q1 2024.
  • Entero Therapeutics, Inc. Debt-to-equity for the quarter ending March 31, 2024 was 94.6 %.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q1 2024 94.6 +372 Mar 31, 2024
Q4 2023 116 +316 Dec 31, 2023
Q3 2023 121 +308 Sep 30, 2023
Q2 2023 392 +588 Jun 30, 2023
Q1 2023 -277 +98 +26.1% Mar 31, 2023
Q4 2022 -199 -942 -127% Dec 31, 2022
Q3 2022 -187 -570 -149% Sep 30, 2022
Q2 2022 -197 -284 -326% Jun 30, 2022
Q1 2022 -375 -493 -419% Mar 31, 2022
Q4 2021 742 +515 +227% Dec 31, 2021
Q3 2021 383 +288 +306% Sep 30, 2021
Q2 2021 86.9 -145 -62.5% Jun 30, 2021
Q1 2021 118 -44 -27.2% Mar 31, 2021
Q4 2020 227 +53.2 +30.6% Dec 31, 2020
Q3 2020 94.4 -71.6 -43.2% Sep 30, 2020
Q2 2020 232 +111 +91.6% Jun 30, 2020
Q1 2020 162 +81.1 +101% Mar 31, 2020
Q4 2019 174 +97.4 +128% Dec 31, 2019
Q3 2019 166 +71 +74.7% Sep 30, 2019
Q2 2019 121 -1.34 -1.1% Jun 30, 2019
Q1 2019 80.6 -77.6 -49.1% Mar 31, 2019
Q4 2018 76.4 -74.4 -49.3% Dec 31, 2018
Q3 2018 95 -34.1 -26.4% Sep 30, 2018
Q2 2018 122 +1.1K Jun 30, 2018
Q1 2018 158 Mar 31, 2018
Q4 2017 151 Dec 31, 2017
Q3 2017 129 Sep 30, 2017
Q2 2017 -973 Jun 30, 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.